EICHORCondition: HIV Preexposure Prophylaxis · Sponsor: Merck Sharp & Dohme LLC
The main purpose of the study is to evaluate the safety and tolerability of oral Islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men and who are at high risk of HIV-1 infection with 48 or 96 weeks of treatment and a minimum follow-up of 42 days.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0007) | Birmingham, Alabama, United States | — |
| UCLA Center for Clinical AIDS Research and Education ( Site 0011) | Los Angeles, California, United States | — |
| Global Research Institute ( Site 0031) | Los Angeles, California, United States | — |
| Bridge HIV - San Francisco Department of Public Health ( Site 0003) | San Francisco, California, United States | — |
| The GW Medical Faculty Associates-Medicine ( Site 0033) | Washington D.C., District of Columbia, United States | — |
| Midway Immunology and Research Center ( Site 0014) | Ft. Pierce, Florida, United States | — |
| University of Miami Miller School of Medicine-Infectious Disease ( Site 0029) | Miami, Florida, United States | — |
| Orlando Immunology Center ( Site 0010) | Orlando, Florida, United States | — |
| Ponce De Leon Center Grady Health ( Site 0032) | Atlanta, Georgia, United States | — |
| Howard Brown Health Center ( Site 0004) | Chicago, Illinois, United States | — |
| The University of Mississippi Medical Center ( Site 0012) | Jackson, Mississippi, United States | — |
| Rutgers New Jersey Medical School-Clinical Research Center ( Site 0017) | Newark, New Jersey, United States | — |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04652700